Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04235985 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Chlorhexidine Gluconate Concentration on Skin of Human Subjects Following Multiple Application Times
A Phase 4 study of General Skin Cleansing, sponsored by Molnlycke Health Care AB.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT04235985: Completed Phase 4 study of General Skin Cleansing, sponsored by Molnlycke Health Care AB.
NCT04235985 is a Phase 4 study of General Skin Cleansing that has completed, run by Molnlycke Health Care AB. The registered enrollment target is 26 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04235985, a Phase 4 study of General Skin Cleansing, has completed, sponsored by Molnlycke Health Care AB.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the amount of chlorhexidine gluconate (CHG) present on treated skin of human volunteers following different application times with a test material bathing system. The amount of recovered CHG that resides on the skin following each of the evaluated application times will be evaluated via high performance liquid chromatography with ultraviolet detection (HPLC-UV) and correlated with the MIC values determined separately.
Primary Outcome
To find out how much CHG is left on the skin with different application times
Conditions Studied
Interventions
- COMBINATION_PRODUCT Chlorhexidine Gluconate with HUBS
Study Locations (1)
Montana
- Bioscience Laboratories, Inc - Bozeman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-01-23 |
| Est. Completion | 2020-04-02 |
| Phase | Phase 4 |
What the finished NCT04235985 record still lists
NCT04235985 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with General Skin Cleansing appearing as the primary indexed condition, and to 1 intervention - of which Chlorhexidine Gluconate with HUBS is the first listed.
NCT04235985 reports a single indexed study location in Montana.
Frequently Asked Questions
What is clinical trial NCT04235985 about?
NCT04235985 is a clinical study titled "Evaluation of Chlorhexidine Gluconate Concentration on Skin of Human Subjects Following Multiple Application Times". This study will evaluate the amount of chlorhexidine gluconate (CHG) present on treated skin of human volunteers following different application times with a test material bathing system. The amount of recovered CHG that resides on the skin following each of the evaluated application times will be e...
What is the current status of trial NCT04235985?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2020-01-23. Estimated completion is 2020-04-02.
What conditions does trial NCT04235985 study?
This clinical trial studies the following conditions: General Skin Cleansing.
What interventions are being tested in trial NCT04235985?
The interventions under investigation include: Chlorhexidine Gluconate with HUBS (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04235985?
This trial is sponsored by Molnlycke Health Care AB, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04235985 being conducted?
This trial has 1 study location across Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04235985's enrollment target sits among peer trials
26 1655th of 2000 higher than 333 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI